Compare CTNM & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CTNM | DPG |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.4M | 529.2M |
| IPO Year | 2024 | 2011 |
| Metric | CTNM | DPG |
|---|---|---|
| Price | $13.65 | $15.03 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 512.7K | 56.5K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.08 | $12.34 |
| 52 Week High | $16.91 | $15.15 |
| Indicator | CTNM | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 64.52 |
| Support Level | $11.73 | $14.06 |
| Resistance Level | $14.96 | $15.07 |
| Average True Range (ATR) | 0.94 | 0.17 |
| MACD | -0.21 | 0.02 |
| Stochastic Oscillator | 7.96 | 100.00 |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.